New drug delivers promising survival gains in pancreatic cancer
About 90% of people with pancreatic cancer have pancreatic ductal adenocarcinoma (PDAC), which is driven by an activating mutation in…
Engineered probiotic bacteria boost immune attack against pancreatic cancer
Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat. One major…
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Red meat intake emerges as a potential pancreatic cancer risk factor
A review of nearly 2 million participants links higher red meat intake to pancreatic cancer risk, while the…
Experimental drug shows promise against NRAS-driven melanoma
A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective…
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
New study identifies potential compound for pancreatic cancer treatment
Announcing a new article publication in BIO Integration. Fat mass and obesity-associated protein (FTO), an epitranscriptomic regulator, has…
Why Revolution Medicines (RVMD) Is Up 6.2% After Early Zoldonrasib Pancreatic Cancer Data And What’s Next
In late June and early July 2026, Revolution Medicines reported Phase 1/2 data showing that its RAS G12D…
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Targeted therapy doubles progression-free survival in rare bile duct cancer
Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid…
Highly-sensitive blood test detects hidden traces of pancreatic cancer
Northwestern Medicine scientists have demonstrated that a highly sensitive blood test can detect traces of pancreatic cancer missed…
Novel IL1RAP therapy advances toward pancreatic cancer clinical trial
Blocking IL1RAP, a receptor that sits at a key control point in inflammatory signaling, can disrupt the tumor-driven…